Universität zu Köln

Merola, Elettra, Rinke, Anja, Partelli, Stefano, Gress, Thomas M., Andreasi, Valentina ORCID: 0000-0002-3793-2982, Kollar, Attila, Perren, Aurel ORCID: 0000-0002-6819-6092, Christ, Emanuel, Panzuto, Francesco ORCID: 0000-0003-2789-4289, Pascher, Andreas, Jann, Henning, Arsenic, Ruza, Cremer, Birgit, Kaemmerer, Daniel, Kump, Patrizia, Lipp, Rainer W., Agaimy, Abbas, Wiedenmann, Bertram, Falconi, Massimo ORCID: 0000-0001-9654-7243 and Pavel, Marianne E. (2020). Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms? Ann. Surg. Oncol., 27 (5). S. 1348 - 1356. NEW YORK: SPRINGER. ISSN 1534-4681

Full text not available from this repository.

Abstract

Background While platinum-based chemotherapy represents the standard treatment for advanced grade 3 (G3) neuroendocrine neoplasms (NENs) according to the European Neuroendocrine Tumor Society guidelines, the role of radical-intended surgery in these patients, as well as the use of adjuvant chemotherapy, are still controversial. The aim of the present work is to describe, in a retrospective series of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) G3, the overall survival (OS) rate and risk factors for death after radical surgery. Secondary aims are the description of median recurrence-free survival (RFS) and of the role of adjuvant chemotherapy. Patients and Methods Multicenter analysis of a series of stage I-III GEP-NEN G3 patients receiving radical surgery (R0/R1) with/without adjuvant chemotherapy was performed. Results Sixty patients from eight neuroendocrine tumor (NET) referral centers, with median follow-up of 23 months (5-187 months) were evaluated. While 28.6% of cases had NET G3, 71.4% had neuroendocrine carcinoma G3 (NEC G3). The 2-year OS rate after radical surgery was 64.5%, with a statistically significant difference in terms of Ki67 threshold (cut-off 55%, P = 0.03) and tumor differentiation (NEC G3 vs. NET G3, P = 0.03). Median RFS after radical surgery was 14 months, and 2-year RFS rate was 44.9%. Use of adjuvant chemotherapy provided no benefit in terms of either OS or RFS in this series. Conclusions Surgery with radical intent might represent a valid option for GEP-NEN G3 patients with locoregional disease, especially with Ki67 value <= 55%.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Merola, Elettra UNSPECIFIED UNSPECIFIED UNSPECIFIED Rinke, Anja UNSPECIFIED UNSPECIFIED UNSPECIFIED Partelli, Stefano UNSPECIFIED UNSPECIFIED UNSPECIFIED Gress, Thomas M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Andreasi, Valentina UNSPECIFIED orcid.org/0000-0002-3793-2982 UNSPECIFIED Kollar, Attila UNSPECIFIED UNSPECIFIED UNSPECIFIED Perren, Aurel UNSPECIFIED orcid.org/0000-0002-6819-6092 UNSPECIFIED Christ, Emanuel UNSPECIFIED UNSPECIFIED UNSPECIFIED Panzuto, Francesco UNSPECIFIED orcid.org/0000-0003-2789-4289 UNSPECIFIED Pascher, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Jann, Henning UNSPECIFIED UNSPECIFIED UNSPECIFIED Arsenic, Ruza UNSPECIFIED UNSPECIFIED UNSPECIFIED Cremer, Birgit UNSPECIFIED UNSPECIFIED UNSPECIFIED Kaemmerer, Daniel UNSPECIFIED UNSPECIFIED UNSPECIFIED Kump, Patrizia UNSPECIFIED UNSPECIFIED UNSPECIFIED Lipp, Rainer W. UNSPECIFIED UNSPECIFIED UNSPECIFIED Agaimy, Abbas UNSPECIFIED UNSPECIFIED UNSPECIFIED Wiedenmann, Bertram UNSPECIFIED UNSPECIFIED UNSPECIFIED Falconi, Massimo UNSPECIFIED orcid.org/0000-0001-9654-7243 UNSPECIFIED Pavel, Marianne E. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-127783
DOI:	10.1245/s10434-019-08049-5
Journal or Publication Title:	Ann. Surg. Oncol.
Volume:	27
Number:	5
Page Range:	S. 1348 - 1356
Date:	2020
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1534-4681
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PROGNOSTIC-FACTORS; HIGH-GRADE; LIVER METASTASES; CARCINOMA; TUMORS; SURVIVAL; THERAPY Multiple languages Oncology; Surgery Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/12778